The immunotherapy drug atezolizumab ( Tecentriq ) to treat advanced alveolar soft part sarcoma has received FDA approval following a clinical trial led by NCI.
Category: Oncology
NCI clinical trial leads to atezolizumab approval for advanced alveolar soft part sarcoma
The immunotherapy drug atezolizumab ( Tecentriq ) to treat advanced alveolar soft part sarcoma has received FDA approval following a clinical trial led by NCI.
Erratum to “P-309 In vitro drug screening of patient-specific tumoroids to predict chemotherapeutic treatment response in pancreatic ductal adenocarcinoma: An interim analysis”
The organizers regret that P – 309 was left out of the original ESMO 24th World Congress on Gastrointestinal Cancer 2022 Abstract Book. This abstract reads as follows:
Statement from Monica M. Bertagnolli, M.D., Director, National Cancer Institute, National Institutes of Health
a statement from the National Cancer Institute regarding NCI Director Monica M. Bertagnolli’s recent diagnosis of early breast cancer.
Statement from Monica M. Bertagnolli, M.D., Director, National Cancer Institute, National Institutes of Health
a statement from the National Cancer Institute regarding NCI Director Monica M. Bertagnolli’s recent diagnosis of early breast cancer.
Annual Report to the Nation: Cancer deaths continue downward trend; modest improvements in survival for pancreatic cancer
In the most recent Annual Report to the Nation on the Status of Cancer, men, women, children, adolescents, and young adults in every significant racial and ethnic group in the United States continued to experience a decline in overall cancer death rates from 2015 to 2019.
Annual Report to the Nation: Cancer deaths continue downward trend; modest improvements in survival for pancreatic cancer
In the most recent Annual Report to the Nation on the Status of Cancer, men, women, children, adolescents, and young adults in every significant racial and ethnic group in the United States continued to experience a decline in overall cancer death rates from 2015 to 2019.